// App-Quantinova.ai

EP740 : PRELIMINARY ANALYSIS OF A PHASE 1 STUDY OF NEXI-002 AUTOLOGOUS MULTI-AGENT-SPECIFIC CD8+ T CELLS FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Researchers

Presenter

  • Andrew Kin

Principal Investigators

  • Maung Myo Htut

  • Juan C. Varela

  • Vineetha Edavana

  • Sojung Kim

  • Lauren Suarez

  • Mathias Oelke

  • Daniel Bednarik

  • Robert D. Knight

  • Monzr M. Al Malki

Medical Centers

  • Hematology and Hematopoietic Cell Transplantation,City of Hope National Medical Center,Duarte,Vereinigte Staaten

  • Marrow Transplant Program,Advent Health Blood and Marrow Program,Orlando, FL,United States

  • Division of Oncology,Karmanos Center/Wayne State Universityte,Detroit, MI,United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Cluster of differentiation 8A

  • Syndecan-1

  • WT1 Transcription Factor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved